TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07311993: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Sponsor: Cellectar Biosciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$8,482,320

Rescue Site Savings

+$5,592,048

Unlock Full NCT07311993 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07311993 Rescue Dossier →